RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques.

RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques.

Publication date: Dec 29, 2023

Antibodies provide critical protective immunity against COVID-19, and the Fc-mediated effector functions and mucosal antibodies also contribute to the protection. To expand the characterization of humoral immunity stimulated by subunit protein-peptide COVID-19 vaccine UB-612, preclinical studies in non-human primates were undertaken to investigate mucosal secretion and the effector functionality of vaccine-induced antibodies in antibody-dependent monocyte phagocytosis (ADMP) and antibody-dependent NK cell activation (ADNKA) assays. In cynomolgus macaques, UB-612 induced potent serum-neutralizing, RBD-specific IgG binding, ACE2 binding-inhibition antibodies, and antibodies with Fc-mediated effector functions in ADMP and ADNKA assays. Additionally, immunized animals developed mucosal antibodies in bronchoalveolar lavage fluids (BAL). The level of mucosal or serum ADMP and ADNKA antibodies was found to be UB-612 dose-dependent. Our results highlight that the novel subunit UB-612 vaccine is a potent B-cell immunogen inducing polyfunctional antibody responses contributing to anti-viral immunity and vaccine efficacy.

Open Access PDF

Concepts Keywords
Immunogen ADCP
Macaques ADMP
Protective ADNKA
Viral antibody
Fc-mediated effector function
non-human primates


Type Source Name
disease VO peptide vaccine
disease VO UB-612
disease MESH COVID-19
disease VO COVID-19 vaccine
disease VO vaccine
disease VO immunized
drug DRUGBANK Dimercaprol
disease VO dose
disease IDO cell
disease VO vaccine efficacy
disease VO USA
drug DRUGBANK Coenzyme M
drug DRUGBANK Stavudine
disease VO Glycoprotein
disease MESH viral infections
drug DRUGBANK Bisoprolol
disease MESH death
disease MESH infection
disease VO subunit vaccine
drug DRUGBANK Phosphate ion
disease VO vaccinated
disease IDO host
disease VO vaccination
disease VO Viruses
drug DRUGBANK Angiotensin II
drug DRUGBANK Aluminium phosphate
disease VO immunization
disease IDO facility
disease VO injection
disease IDO assay
disease VO titer
drug DRUGBANK Rasagiline
disease VO device
drug DRUGBANK Methylergometrine
drug DRUGBANK Methylcellulose
drug DRUGBANK Formaldehyde
drug DRUGBANK Gentian violet cation
drug DRUGBANK Water
disease IDO blood
drug DRUGBANK Brefeldin A
disease VO dead
disease VO protocol
disease VO ANOVA
disease VO vaccine dose
disease IDO production
disease IDO replication
disease VO active immunization
disease VO organization
disease MESH reinfection
drug DRUGBANK Caffeine
drug DRUGBANK Sodium hydroxide
disease MESH Respiratory Syncytial Virus Infection
disease MESH Sequelae
disease MESH AIDS
disease MESH infectious diseases
disease MESH cancer
disease IDO site
disease MESH Alzheimer’s disease
disease MESH chronic diseases
disease VO vaccine effectiveness
disease MESH Allergy

Original Article

(Visited 1 times, 1 visits today)